Drug Profile
Research programme: candidiasis therapeutics - Bionex Pharmaceuticals/University of Medicine & Dentistry of New Jersey
Latest Information Update: 28 Dec 2020
Price :
$50
*
At a glance
- Originator Bionex Pharmaceuticals
- Developer Bionex Pharmaceuticals; University of Medicine & Dentistry of New Jersey
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Candidiasis
Most Recent Events
- 28 Dec 2020 No recent reports of development identified for research development in Candidiasis in USA (PO)
- 15 Nov 2016 Early research in Candidiasis in USA (PO)